Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A Consensus Statement of the German-Speaking Society for Reconstructive Microsurgery (GSRM): Closure of the DIEP/ms-TRAM Flap Donor-Site Defect].

Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...·2026
Same author

Understanding and Advancing Wound Healing in the Era of Multi-Omic Technology.

Bioengineering (Basel, Switzerland)·2026
Same author

Fibroblasts of disparate developmental origins harbor anatomically variant scarring potential.

Cell·2026
Same author

NFAT mediates pro-tumorigenic inflammation in cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.

Cell reports·2026
Same author

The Challenge of Healing Wounds in Radiation-Injured Skin.

Advances in wound care·2025
Same author

Clinical Features and Mechanisms of Differential Wound Healing and Scarring Across Anatomical Sites.

Advances in wound care·2025
Same journal

Assessment of hESC-IMRC-Exo for Cardiac and Cerebral Injuries Post-Cardiac Arrest Resuscitation: Safety, Pharmacokinetics, and Efficacy.

Journal of cellular and molecular medicine·2026
Same journal

Dynamic Transcriptomic Profiling of Mouse Endometrium Across the Estrous Cycle Reveals Phase-Specific Regulatory Networks Underlying Cyclic Remodelling.

Journal of cellular and molecular medicine·2026
Same journal

Ellagic Acid Attenuates Oxidative Stress and Improves Cardiovascular Function Following Myocardial Infarction in Ovariectomized Rats.

Journal of cellular and molecular medicine·2026
Same journal

Investigation of the Effect of Triacetyl Resveratrol on Epithelial-Mesenchymal Transition in Human Lung Cancer Cell Lines.

Journal of cellular and molecular medicine·2026
Same journal

Anti-HMGB1 Antibody Therapy Ameliorates Depression Following Spinal Cord Injury in Rats by Inhibiting Ferroptosis.

Journal of cellular and molecular medicine·2026
Same journal

METTL3/YTHDF1-Driven SURF6 Promotes Prostate Cancer Stemness via CDK4.

Journal of cellular and molecular medicine·2026
See all related articles
  1. Home
  3. Deferoxamine Improves Radiation-induced Peripheral Neuropathy.
  1. Home
  3. Deferoxamine Improves Radiation-induced Peripheral Neuropathy.

Related Experiment Video

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

Deferoxamine Improves Radiation-Induced Peripheral Neuropathy.

Christopher V Lavin1,2, Alexander Z Fazilat1, Carter B Kendig1

  • 1Hagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.

Journal of Cellular and Molecular Medicine
|June 8, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Deferoxamine (DFO) shows promise in treating radiation-induced peripheral neuropathy (RIPN), a common side effect of radiation therapy (XRT). This study found DFO improved sensorimotor function and nerve regeneration in mice with RIPN.

Keywords:
demyelinationferroptosisfibrosisnerve injuryperipheral nerveradiationradiotherapyreactive oxygen speciesregeneration

Related Experiment Videos

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Background:

  • Radiation-induced peripheral neuropathy (RIPN) is a debilitating complication following radiation therapy (XRT).
  • Limited effective treatment options currently exist for RIPN.
  • Deferoxamine (DFO) has demonstrated efficacy in managing radiation-induced dermal fibrosis.

Purpose of the Study:

  • To investigate the therapeutic potential of Deferoxamine (DFO) in mitigating radiation-induced peripheral neuropathy (RIPN).

Main Methods:

  • A murine model was established using 30Gy fractionated XRT.
  • Mice were subsequently treated with DFO, saline, or no treatment.
  • Functional assessments included footprint analysis, cold allodynia, and monofilament testing.
  • Immunofluorescent staining assessed myelination (MPZ) and axonal regeneration (GAP43).

Main Results:

  • DFO treatment significantly improved motor deficits and reduced cold allodynia in mice.
  • A positive trend was observed in monofilament testing.
  • DFO enhanced remyelination (MPZ staining) and promoted axonal regeneration (GAP43 staining).

Conclusions:

  • Deferoxamine (DFO) demonstrates therapeutic benefits for radiation-induced peripheral neuropathy (RIPN) in a murine model.
  • DFO improves sensorimotor function and promotes nerve repair.
  • These findings offer a potential disease-modifying treatment for patients experiencing RIPN as a side effect of XRT.